Drugs & Targets FDA approves Pluvicto for metastatic castration-resistant prostate cancer March 25, 2022Vol.48 No.12
Drugs & Targets PathAI, Cleveland Clinic to build digital pathology infrastructure, support use of AI-powered pathology algorithms in research and clinical care March 25, 2022Vol.48 No.12
Drugs & Targets FDA approves FoundationOne CDx as companion diagnostic for EGFR therapeutics targeting exon 19 deletions or exon 21 substitutions in NSCLC March 18, 2022Vol.48 No.11
Drugs & Targets Strata Oncology Sentinel Trial for personalized cancer recurrence monitoring enrolls first patient March 18, 2022Vol.48 No.11
Drugs & Targets FDA approves Opdivo and platinum-doublet chemotherapy for early-stage NSCLC March 11, 2022Vol.48 No.10
Drugs & Targets FDA grants priority review to Tibsovo in combination with azacitidine in previously untreated IDH1-mutated AML March 11, 2022Vol.48 No.10
Drugs & Targets FDA clinical trial guidances touch on Biden administration’s goals for advancing development of cancer treatments March 11, 2022Vol.48 No.10
Drugs & Targets Six months after court-ordered deadline, FDA hasn’t ruled on major e-cigarette manufacturers’ product applications, advocates say March 11, 2022Vol.48 No.10
Drugs & Targets MGH, Lunaphore to develop spatial biology-based cancer diagnostics February 25, 2022Vol.48 No.08
Drugs & Targets FDA grants Fast Track designation to IO-202, anti-LILRB4 myeloid checkpoint inhibitor for AML February 18, 2022Vol.48 No.07
